OR WAIT 15 SECS
© 2021 MJH Life Sciences and Ophthalmology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
The short-term clinical experience with intravitreal bevacizumab (Avastin, Genentech) supports growing perception that treatment is safe and effective for neovascular age-related macular degeneration.